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Abstract
Several recent studies suggest functional and molecular interactions between striatal adenosine
A2A and cannabinoid CB1 receptors. Here we demonstrate that A2A receptors selectively modulate
reinforcing effects of cannabinoids. We studied effects of A2A receptor blockade on the
reinforcing effects of delta-9-tetrahydrocannabinol (THC) and the endogenous CB1 receptor
ligand anandamide under a fixed-ratio (FR) schedule of intravenous drug injection in squirrel
monkeys. A low dose of the selective adenosine A2A receptor antagonist MSX-3 (1 mg/kg) caused
downward shifts of THC and anandamide dose-response curves. In contrast, a higher dose of
MSX-3 (3 mg/kg) shifted THC and anandamide dose-response curves to the left. MSX-3 did not
modify cocaine or food-pellet self-administration. Also, MSX-3 neither promoted reinstatement of
extinguished drug-seeking behavior nor altered reinstatement of drug-seeking behavior by non-
contingent priming injections of THC. Finally, using in-vivo microdialysis in freely-moving rats, a
behaviorally active dose of MSX-3 significantly counteracted THC-induced, but not cocaine-
induced, increases in extracellular dopamine levels in the nucleus accumbens shell. The significant
and selective results obtained with the lower dose of MSX-3 suggest that adenosine A2A
antagonists acting preferentially at presynaptic A2A receptors might selectively reduce reinforcing
effects of cannabinoids that lead to their abuse. However, the appearance of potentiating rather
than suppressing effects on cannabinoid reinforcement at the higher dose of MSX-3 would likely
preclude the use of such a compound as a medication for cannabis abuse. Adenosine A2A
antagonists with more selectivity for presynaptic versus postsynaptic receptors could be potential
medications for treatment of cannabis abuse.
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INTRODUCTION
Adenosine plays a very important modulatory role in striatal function. Adenosine A2A
receptors are concentrated in the striatum more than anywhere else in the brain and are
strategically located, both presynaptically and postsynaptically, to modulate glutamatergic
neurotransmission (Ciruela et al. 2006; Ferré et al. 2005; Ferré et al. 2007; Hettinger et al.
2001; Quiroz et al. 2009). Similarly, cannabinoid CB1 receptors, which mediate the central
effects of Δ9-tetrahydrocannabinol (THC) and endocannabinoids, are also abundantly
expressed in the striatum (Herkenham et al. 1991) and are located both presynaptically and
postsynaptically, to modulate glutamatergic neurotransmission (Ferré et al. 2009; Fusco et
al. 2004; Hohmann & Herkenham 2000; Kofalvi et al. 2005; Pickel et al. 2004; Pickel et al.
2006).
Several studies have suggested functional and molecular interactions (receptor
heteromerization) between striatal adenosine A2A and cannabinoid CB1 receptors (for recent
reviews, see Ferré et al. 2009; Ferré et al. 2010). We recently found that the motor
depressant effects of intra-striatal administration of the cannabinoid CB1 receptor agonist
WIN 55,212-2 were counteracted by A2A receptor blockade (Carriba et al. 2007). Moreover,
Soria and colleagues (2004) reported decreased development of conditioned place
preferences with THC in A2A receptor-deficient mice, which suggests that rewarding effects
of cannabinoids might also depend on striatal A2A-CB1 receptor interactions. Yao et al.
(2006) showed that μ-opiate and CB1 receptors act synergistically in nucleus accumbens-
striatal neurons and that this synergy is regulated by A2A receptors. In that study,
pretreatment with the A2A-receptor antagonist MSX-3 eliminated heroin-induced
reinstatement of extinguished drug-seeking behavior in rats that had previously self-
administered heroin. However, the role of adenosine A2A receptors in the reinforcing effects
of cannabinoids has not been investigated. Thus, it is unknown whether adenosine A2A
antagonists have any potential as a treatment of cannabis abuse.
The aim of this study was to investigate the role of A2A-CB1 receptor interactions in the
reinforcing effects of cannabinoid CB1 receptor agonists in squirrel monkeys. The squirrel
monkey (Saimiri sciureus) is a primate species we have used extensively to investigate the
reinforcing effects of cannabinoids (Justinová et al. 2003; Justinová et al. 2004; Justinová et
al. 2008b; Justinová et al. 2005; Tanda, Munzar & Goldberg 2000). In the present study, we
examined whether the selective A2A-receptor antagonist MSX-3 would alter self-
administration maintained by THC, the endogenous CB1-receptor agonist anandamide,
cocaine, or food under a fixed-ratio (FR) schedule. Also, to assess the potential of MSX-3 to
precipitate relapse to abuse in abstinent individuals, we studied whether it would reinstate
extinguished drug-seeking behavior or alter the reinstatement of extinguished drug-seeking
behavior produced by THC or cocaine. Finally, we studied whether MSX-3 can alter THC-




Sixteen adult male squirrel monkeys (Saimiri sciureus) weighing 0.8 to 1.1 kg were housed
in individual cages in a temperature- and humidity-controlled room with unrestricted access
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to water. Monkeys were fed (approximately two hours after the session) a daily food ration
consisting of five biscuits of high protein monkey diet (Lab Diet 5045, PMI Nutrition
International, Richmond, Indiana) and two pieces of Banana Softies (Bio-Serv, Frenchtown,
NJ) that maintained their body weights at a constant level throughout the study. Fresh fruits,
vegetables and environmental enrichment were provided daily. In vivo microdialysis
experiments were performed in male Sprague Dawley rats, weighing 300-350 g. Animals,
housed in groups of three, had unlimited access to water and food. Animals were maintained
in facilities fully accredited by AAALAC and experiments were conducted in accordance
with guidelines of the Institutional Animal Care and Use Committee of the Intramural
Research Program, NIDA, NIH, DHHS.
One group of four monkeys was used for experiments with the anandamide self-
administration baseline: all monkeys had a history of anandamide self-administration (6754,
67F4, 70F4, 1568). Another group of four monkeys was used for experiments with the THC
self-administration baseline: three monkeys had a history of THC self-administration (434,
37B, 453) and one monkey had a prior history of anandamide self-administration (66B2).
Another group of four monkeys was used for experiments with the cocaine self-
administration baseline; all monkeys had a prior history of cocaine self-administration
(70F7, 01714B, 5045, 39B). A group of five monkeys was used for studying responding
reinforced by food pellets (34A, 27B, 30A, 1549, 39B). Monkey 39B was first trained to
respond for food pellets. After testing of an MSX-3 dose-response curve was finished,
monkey 39B was switched to cocaine self-administration in order to increase the size of this
experimental group of monkeys to four, as with the anandamide and THC groups.
Apparatus
Experimental chambers and other apparatus used in this study were the same as previously
described (Justinová et al. 2003). Monkeys were surgically prepared with chronic indwelling
venous catheters (polyvinyl chloride) (Goldberg 1973). The catheters were connected to
polyethylene tubing, which passed out of the isolation chambers where they attached to
motor-driven syringe pumps. The syringe pumps were calibrated so that duration of each
injection was 0.2 s and injection volume was 0.2 ml. Before the start of each session,
monkeys were placed into Plexiglas chairs and restrained in the seated position by waist
locks. Before the start of each session, catheters were flushed with 1 ml of saline and one
injection was delivered (calculated to fill the dead space of the catheter which was about 0.2
ml).
Self-administration procedure
Fixed-ratio schedule of drug injection—A fixed-ratio schedule of intravenous drug
injection was used to evaluate drug reinforcement because it provides reliable and
reproducible positive reinforcing effects with cannabinoids, including THC and
endocannabinoids (Justinová et al. 2003; Justinová et al. 2005; Tanda et al. 2000) and is a
valid procedure for evaluating abuse liability of cannabinoids (Justinová et al. 2008a;
Panlilio & Goldberg 2007; Panlilio, Justinová & Goldberg 2010). At the start of the session,
a white house light was turned off and a green stimulus light was turned on. In the presence
of the green light, monkeys were required to make 10 responses on the lever (10-response,
fixed-ratio schedule of reinforcement; FR10) to produce an injection of anandamide, THC or
cocaine. The completion of 10 responses on the lever turned off the green light and
produced an intravenous (i.v.) injection of 40 μg/kg of anandamide, 4 μg/kg of THC, or 30
μg/kg of cocaine, and each injection was paired with a 2-s illumination of an amber stimulus
light. Each injection was followed by a 60-s timeout period, during which the chamber was
dark and lever presses had no programmed consequences. One-hour sessions were
conducted five days per week (typically Monday to Friday).
Justinová et al. Page 3













All monkeys had learned to respond under the FR10 schedule for the particular training drug
prior to the beginning of this study. When responding for the training dose of drug, which
maintained maximal rates of responding (40 μg/kg/injection anandamide, 4 μg/kg/injection
THC, 30 μg/kg/injection cocaine), was stable for at least five consecutive sessions (less than
15% variability), testing with different doses of the A2A receptor antagonist MSX-3 was
then conducted, with vehicle or different MSX doses (vehicle, 0.1, 0.3, 1 and 3 mg/kg; order
of testing was 1, 0.3, 0.1, and 3 mg/kg; MSX-3 always administered 5 min before the
session i.m.) tested by pretreatment before each of three consecutive sessions followed by
recovery of stable THC, anandamide, or cocaine baseline responding. After testing these
different doses of MSX, monkeys were allowed to self-administer the training dose of THC,
anandamide, or cocaine for 4-5 sessions followed by saline substitution. After reaching a
stable extinction baseline, pretreatment with vehicle or MSX-3 (1 and 3 mg/kg) was again
tested for three sessions. After completing this step, monkeys were returned to baseline self-
administration of the training dose of THC, anandamide, or cocaine, followed by vehicle
extinction. Next, vehicle was replaced by a low dose of THC, anandamide, or cocaine (2.5
μg/kg/injection anandamide, 1 μg/kg/injection THC, 3 μg/kg/injection cocaine) and vehicle
or MSX-3 (1 and 3 mg/kg) was tested by pretreatment. Following further saline extinction
for four to five sessions, monkeys were allowed to self-administer a high dose of the
anandamide (80 μg/kg/injection), THC (8 μg/kg/injection), or cocaine (100 μg/kg/injection)
and MSX-3 was tested by pretreatment for three sessions (1 and 3 mg/kg). Following saline
extinction for four to five sessions, monkeys from the anandamide and THC groups were
allowed to self-administer a lower dose of the drug (1 μg/kg/injection anandamide, 0.5 μg/
kg/injection THC), and MSX-3 was then tested by pretreatment for three sessions (3 mg/kg).
Finally, following saline extinction for four to five sessions, monkeys from the anandamide
and THC groups were allowed to self-administer an intermediate dose of the drug (10 μg/kg/
injection anandamide, 2 μg/kg/injection THC) and MSX-3 was then tested by pretreatment
for three sessions (1 mg/kg).
Before reinstatement testing began, monkeys were again allowed to self-administer the
training dose of THC (4 μg/kg/injection) or cocaine (30 μg/kg/injection) until they reached a
stable baseline. Saline was then substituted for THC or cocaine. After three days of stable
saline extinction, we tested for drug-induced reinstatement of extinguished drug-seeking
behavior by administering pre-session priming injections of MSX-3 (1 or 3 mg/kg, i.m. 5
min before the session) or its vehicle, THC (10 or 40 μg/kg, i.v. immediately before the
session) or its vehicle, or combinations of THC and MSX-3. Each reinstatement test was a
single session and each test was preceded and followed by saline extinction session(s).
Reinstatement tests were conducted in a counterbalanced manner in the THC- and cocaine-
trained monkeys.
In vivo microdialysis experiments
Concentric microdialysis probes with 2 mm-long dialysis membranes were prepared as
described previously (Pontieri, Tanda & Di Chiara 1995). Animals were anesthetized with
Equithesin (NIDA Pharmacy, Baltimore, MD, USA) and probes were implanted in the shell
of the nucleus accumbens (coordinates with respect to bregma: anterior, +2.2; lateral, -1.0;
ventral, 7.7 from the dura). A Ringer solution (in mM) of 147 NaCl, 4 KCl, and 2.2 CaCl2
was pumped through the dialysis probe at a constant rate of 1 μl/min. A dose of 3 mg/kg
MSX-3 was given i.p. 20 min before the administration of THC (3 mg/kg, i.p.) or cocaine (3
mg/kg, i.p.). As previously reported, theses doses of THC and cocaine are equipotent in
increasing extracellular dopamine levels (Solinas et al. 2007; Tanda et al. 2005). The dose
of MSX-3 chosen (3 mg/kg) was the minimal dose previously shown to produce significant
motor activation in the same rat strain (Antoniou et al. 2005). After a washout period of 90
min, samples were collected at 20 min intervals and dopamine content was measured. Each
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animal was used to study the effects of one treatment. At the end of the experiment, rats
were killed with an overdose of Equithesin and methylene blue was perfused through the
probe. The brain was removed and placed in a 10% formaldehyde solution and coronal
sections were cut to verify the probe location. Dopamine content was measured by reverse
high-performance liquid chromatography (HPLC) coupled to electrochemical detector, as
described in detail previously (Pontieri et al. 1995)
Drugs
Anandamide (Arachidonylethanolamide; Tocris Cookson, Inc., Ellisville, MO, USA) and
Δ9-tetrahydrocannabinol (THC; National Institute on Drug Abuse, Bethesda, MD, USA)
were dissolved in a vehicle containing 1% ethanol and 1% Tween 80 and saline. THC was
administered i.v. immediately before the session in reinstatement tests. (-)-Cocaine HCl was
purchased from Sigma Chemical Co. (St. Louis, MO, USA) and dissolved in saline. MSX-3
free acid [phosphoric acid mono-(3-{8-[2-(3-methoxy-phenyl)vinyl]-7-methyl-2,6-dioxo-1-
prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl}propyl) ester] (Hockemeyer, Burbiel & Müller
2004) was synthesized at the Pharmaceutical Institute, University of Bonn, Bonn, Germany.
MSX-3 was dissolved in sterile water with addition of NaOH to obtain the disodium salt and
to correct pH and was administered i.m. (0.3 ml/kg) to monkeys 5 min before each session
in all tests. MSX-3 has been extensively characterized as a very selective A2A receptor
antagonist in rodents (Karcz-Kubicha et al. 2003; Solinas et al. 2005). Although, to our
knowledge, there is no pharmacological data available about MSX-3 in non-human
primates, binding studies indicate a very similar affinity of rodent and human A2A receptors
for this compound (Müller & Ferré 2007). Furthermore, MSX-3 is the only hydrosoluble
A2A receptor antagonist so far available, making it more convenient for systemic
administration. In rat microdialysis experiments, THC, cocaine and MSX-3 were
administered at a dose of 3 mg/kg i.p. (2 ml/kg) and MSX-3 was injected 20 min before the
administration of THC or cocaine. A shorter MSX-3 pretreatment time in monkeys
compared to rats was chosen mostly because of the route of administration (i.m. versus i.p.,
respectively) and the time parameters of the two different types of experiments.
Statistical analyses
Cumulative-response records were obtained during all sessions in order to assess within-
session patterns of responding. Rates of responding during self-administration sessions are
expressed as responses per sec averaged over the one-hr session, with responding during
time-outs not included in calculations. Injections or pellets per session represent total
number of injections or pellets delivered per session. All data are presented as mean ±
S.E.M. For the dose-effect curves (Figure 1 and 2), the last three sessions under each
condition were averaged for each subject and used for analysis. Reinstatement data in Figure
3 are averaged from single session tests.
Statistical analyses were done using one-way and two-way repeated measures ANOVA
(data met the assumptions of the test) to assess differences between vehicle and MSX-3-
pretreatment conditions. Pairwise multiple comparisons were done using Tukey's or
Dunnett's procedures. For the in vivo microdialysis data, two-way ANOVA, followed by
repeated measures ANOVA, and Dunnett's procedure were used. Statistical significance was
accepted at the P < 0.05 level. SigmaStat software (http://www.systat.com) was used for all
statistical analyses.
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Effects of MSX-3 pretreatment on responding reinforced by anandamide, THC, cocaine and
food pellets under FR schedule
Maximal responding was maintained by injection doses of 40 μg/kg of anandamide, 4 μg/kg
of THC, and 30 μg/kg of cocaine, as in previous studies under the same conditions
(Justinová et al. 2003; Justinová et al. 2008a; Tanda et al. 2000), and these injection doses
were first selected for studying the effects of MSX-3 in the present experiments. In this
study, at the 40 μg/kg/injection dose of anandamide, monkeys self-administered an average
of 47.67 ± 1.62 injections per session at a rate of 0.87 ± 0.21 response per sec. At the 4 μg/
kg/injection dose of THC, monkeys self-administered 46.69 ± 2.62 injections per session at
a rate of 0.78 ± 0.23 response per sec. At the 30 μg/kg/injection dose of cocaine, monkeys
self-administered 49.64 ± 2.12 injections per session at a rate of 1.04 ± 0.28 responses per
sec. Monkeys self-administered on average 51.65 ± 0.60 food pellets per session at a rate of
1.31 ± 0.14 responses per sec. There were no statistical differences in rates of responding as
a function of reinforcer (Figure 1; One-way ANOVA: F(3,11) = 1.22, p = 0.35).
Effects of i.m. pretreatment with vehicle or MSX-3 at doses 0.1, 0.3, 1.0, and 3.0 mg/kg on
number of reinforcements and rates of responding with food and with doses of the self-
administered drugs that maintained maximal responding (are shown in Figure 1. MSX-3
doses of 1.0 and 3.0 mg/kg significantly and dose-dependently decreased the number of self-
administered injections of anandamide (F(4,12) = 10.396, p < 0.001) and THC (F(4,8) = 34.66,
p < 0.001), as well as rates of responding (anandamide: F(4,12) = 5.12, p = 0.012; THC: F(4,8)
= 10.14, p = 0.003). MSX-3 did not alter either cocaine or food self-administration at any
dose tested (Cocaine injections: F(4,8) = 0.76, p = 0.58, rates: F(4,8) = 0.92, p = 0.50; food
pellets: F(4,16) = 0.86, p = 0.51, rates: F(4,16) = 0.03, p = 0.99).
Effects of pretreatment with MSX-3 on dose-response curves for anandamide, THC, and
cocaine self-administration
When the injection dose of anandamide, THC or cocaine was varied, classic, inverted, U-
shaped, dose-effect curves were obtained (Figure 2). Anandamide maintained significantly
higher numbers of self-administered injections per session (F(5,14) = 94.91, p < 0.001; Figure
2, left panel) than vehicle at doses of 10, 40 and 80 μg/kg/injection. THC maintained
significantly higher numbers of self-administered injections per session (F(5,10) = 38.06, p <
0.001; Figure 2, middle panel) than vehicle at doses of 1, 2, 4 and 8 μg/kg/injection. Cocaine
maintained significantly higher numbers of self-administered injections per session (F(3,6) =
62.85, p < 0.001; Figure 2, right panel) than vehicle at doses of 30 and 100 μg/kg/injection.
We next tested the effects of pretreatment with 1.0 and 3.0 mg/kg doses of MSX-3 on dose-
response curves for self-administration of anandamide, THC, and cocaine. Pretreatment with
1 or 3 mg/kg doses of MSX-3 did not significantly alter responding for vehicle. A low dose
of MSX-3 (1 mg/kg) caused downward shifts of the anandamide and THC dose-response
curves in monkeys. However, a higher dose 3 mg/kg of MSX-3 shifted the THC and
anandamide dose-response curves to the left. Two-way ANOVA analysis indicated that
there was a significant interaction between anandamide dose and dose of MSX-3 (Figure 2,
left panel; MSX-3 1 mg/kg: F(3,6) = 4.68, p = 0.05; MSX-3 3 mg/kg: F(3,9) = 54.94, p <
0.001), as well as between THC dose and dose of MSX-3 (Figure 2, middle panel; MSX-3 1
mg/kg: F(3,6) = 6.27, p = 0.03; MSX-3 3 mg/kg: F(3,6) = 18.19, p = 0.002). Post-hoc multiple
pairwise comparisons revealed that there were statistically significant differences in the
effects of an anandamide dose of 1 μg/kg/injection after 3 mg/kg of MSX-3 (p < 0.001), an
anandamide dose of 2.5 μg/kg/injection after 3 mg/kg of MSX-3 (p < 0.001), an anandamide
dose of 40 μg/kg/injection after both 1 mg/kg MSX-3 (p = 0.002) and 3 mg/kg MSX-3 (p <
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0.001), and an anandamide dose 80 μg/kg/injection after 3 mg/kg MSX-3 (p = 0.004). In
THC-self-administering monkeys, there were statistically significant differences in the
effects of a THC dose of 0.5 μg/kg/injection after 3 mg/kg of MSX-3 (p = 0.005), a THC
dose of 1 μg/kg/injection after 3 mg/kg of MSX-3 (p = 0.015), a THC dose of 2 μg/kg/
injection after 1 mg/kg of MSX-3 (p = 0.031), a THC dose of 4 μg/kg/injection after both 1
mg/kg MSX-3 (p = 0.006) and 3 mg/kg MSX-3 (p < 0.001), and a THC dose of 8 μg/kg/
injection after 3 mg/kg of MSX-3 (p = 0.05). Neither dose of MSX-3 altered self-
administration of any dose of cocaine (Figure 2, right panel; no significant interaction
between cocaine dose and dose of MSX-3: F(4,8) = 1.31, p = 0.35).
Effects of pretreatment with MSX-3 on reinstatement of extinguished THC- or cocaine-
seeking behavior by a priming injection of THC
The effects of pretreatment with vehicle or MSX-3 (1.0 or 3.0 mg/kg, i.m.) on the
reinstatement of extinguished THC- (Figure 3, panels a, b, c) or cocaine-seeking (Figure 3,
panels d, e, f) behavior by priming injections of vehicle or THC (10 or 40 μg/kg, i.v.) were
studied in a counterbalanced manner in both groups of monkeys. Pretreatment with either
dose of MSX-3 had no effect on drug-seeking behavior in both groups of monkeys after a
priming injection of THC vehicle (Figure 3, panels a and d; compared with MSX-3 vehicle
+ THC vehicle prime combination).
The 10 μg/kg priming dose of THC produced a significant reinstatement of drug-seeking
behavior in both groups of monkeys (Figure 3; THC group, panel b: F(3,9) = 24.84, p <
0.001; cocaine group, panel e: F(3,6) = 28.02, p < 0.001; compared with MSX-3 vehicle +
THC vehicle prime combination). Pretreatment with 1.0 or 3.0 mg/kg of MSX-3 did not
alter the reinstatement of drug-seeking behavior by 10 μg/kg THC in either group of
monkeys (Figure 3, panels b and e: compared with MSX-3 vehicle + THC 10 μg/kg prime
combination).
The 40 μg/kg priming dose of THC also produced a significant reinstatement of drug-
seeking behavior in both groups of monkeys (Figure 3; THC group, panel c: F(3,6) = 14.33, p
= 0.004; cocaine group, panel f: F(3,6) = 12.20, p = 0.006; compared with MSX-3 vehicle +
THC vehicle prime combination). Pretreatment with 1.0 or 3.0 mg/kg of MSX-3 also did not
alter the reinstatement of drug-seeking behavior by 40 μg/kg THC in either group of
monkeys (Figure 3, panels c and f: compared with MSX-3 vehicle + THC 40 μg/kg prime
combination).
Effects of pretreatment with MSX-3 on THC- and cocaine-induced increases in extracellular
levels of dopamine in the nucleus accumbens shell of rats
THC (3 mg/kg, i.p.) produced a significant increase (of almost 100% increase versus basal
values) in extracellular levels of dopamine in the shell of the nucleus accumbens in Sprague-
Dawley rats (Figure 4, upper panel; F(5,25) = 5.58 p = 0.0001). A 3 mg/kg dose of MSX-3
(i.p.), which is the minimal dose that produces a significant motor activation in Sprague-
Dawley rats (Karcz-Kubicha et al. 2003), produced a small but significant decrease in
extracellular dopamine levels (Figure 4, upper panel; F(5,53) = 3.03 p = 0.021). After
pretreatment with MSX-3 (3 mg/kg, i.p.), THC (3 mg/kg, i.p.) also elevated dopamine levels
(Figure 4, upper panel; F(5,35) = 2.74 p = 0.042), but the effect was significantly attenuated
compared with the effect of THC alone (Two-way ANOVA; treatment effect: F(1,40) =
7.517 p = 0.021). On the other hand, the increase in extracellular dopamine levels induced
by an equipotent dose of cocaine (3 mg/kg, i.p.) (Figure 4, lower panel; F(6, 30) = 5.465 p =
0.001) was not attenuated after pretreatment with MSX-3 (3 mg/kg, i.p.) (Two-way
ANOVA; treatment effect: F(1, 81) = 0.99 p = 0.32).
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The present results show that the systemic administration of a low dose (1 mg/kg) of the
adenosine A2A receptor antagonist MSX-3 can selectively reduce the reinforcing effects of
doses of THC and anandamide that maintain peak rates of responding in squirrel monkeys
under a FR schedule. This was demonstrated by downward shifts of the anandamide and
THC dose-response curves. However, a higher dose (3 mg/kg) of MSX-3 produced a shift to
the left of the dose-response curves for THC and anandamide. In contrast, over a range of
doses, MSX-3 did not alter the reinforcing effects of cocaine or food under an identical FR
schedule, which indicates that our findings with MSX-3 are pharmacologically selective.
Although peak rates of responding for THC, anandamide, cocaine, and food were similar
under the FR schedule, it has been suggested that responding for THC and anandamide
might be more sensitive to disruption than responding for cocaine or food. This does not
seem to be the case, because we have seen in the same subjects that MPEP, an antagonist at
metabotropic glutamate receptors subtype 5 (mGlu5), selectively reduces responding for
cocaine and food pellets at a dose that does not affect responding for THC (unpublished
observations). MPEP has been previously shown to produce similar reductions in
responding for cocaine under the same conditions in squirrel monkeys ((Platt, Rowlett &
Spealman 2008). Finally, the present study shows that A2A receptor blockade neither
reinstates extinguished drug-seeking behavior nor alters THC-induced reinstatement of
drug-seeking behavior in monkeys with cannabinoid- or cocaine-self-administration
histories. Thus, our results suggest that adenosine A2A-receptor antagonists – which have
demonstrated anti-parkinsonian and neuroprotective effects in rodent models (for review see
Takahashi, Pamplona & Prediger 2008) – can reduce the reinforcing effects of cannabinoids
under certain conditions, without risk of provoking relapse to drug use in abstinent
individuals.
The main anatomical target for the reinforcing effects of cannabinoid CB1-receptor agonists
is still a matter of debate, with some studies favoring the ventral tegmental area and others
the ventral striatum (for reviews, see Gardner 2005; Lupica, Riegel & Hoffman 2004). In
view of the preferential expression of A2A receptors in the striatum, the present results
strongly support the striatal hypothesis. A2A receptors are preferentially localized in the
dendritic spines of striatopallidal GABAergic enkephalinergic neurons, but also
presynaptically in glutamatergic terminals that make contact with GABAergic
dynorphinergic neurons (Ciruela et al. 2006; Ferré et al. 2007; Hettinger et al. 2001). In the
striatum, CB1 receptors are also located in the dendritic spines of GABAergic neurons,
including striatopallidal neurons, and on glutamatergic (and GABAergic) nerve terminals
(Fusco et al. 2004; Hohmann & Herkenham 2000; Kofalvi et al. 2005; Pickel et al. 2004;
Pickel et al. 2006). Postsynaptic A2A-CB1 receptor interactions in GABAergic
enkephalinergic neurons cannot readily explain the counteraction by the lower dose of
MSX-3 (1 mg/kg) of the effects of THC and anandamide observed in the present study. If
anything, postsynaptic A2A receptor blockade would be expected to potentiate the
reinforcing effects of cannabinoids, by its ability to potentiate the effects of endogenous
dopamine on dopamine D2 receptors, by means of antagonistic A2A-D2 receptor interactions
(Ferré et al. 1997; Ferré et al. 2007). However, a postsynaptic A2A-CB1 receptor interaction
could be involved in the potentiation by the higher dose of MSX-3 (3 mg/kg) of the effects
of THC and anandamide, as it is also probably involved in the previously described ability
of MSX-3 to counteract the motor depression induced by CB1 receptor agonists (Andersson
et al. 2005; Carriba et al. 2007).
A common molecular mechanism contributing to the development of addiction, that is
shared by drugs of abuse (including cannabinoids) is their ability to increase levels of
extracellular dopamine in the shell of the nucleus accumbens (Di Chiara 2002; Koob 1992;
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Robbins & Everitt 1996). The systemic administration of THC induces dopamine release in
the nucleus accumbens (Chen et al. 1990; Solinas et al. 2007; Tanda, Pontieri & Di Chiara
1997), although the underlying mechanism has not yet been well established. Although CB1
receptors in the ventral tegmental area (VTA) have been suggested to be involved, in vivo
administration of THC directly into the VTA does not induce dopamine release in the
nucleus accumbens, while direct infusion of THC in the nucleus accumbens does (Gardner
2005; Lupica et al. 2004; Schlicker & Kathmann 2001). It has been suggested that
presynaptic CB1 receptors that control striatal glutamate release (Robbe et al. 2001), are
main targets for the dopamine-releasing effects of cannabinoids, by decreasing the
excitability of the striatal GABAergic dynorphinergic neurons that project to the
mesencephalon and tonically inhibit dopaminergic cells in the VTA (Schlicker & Kathmann
2001). Therefore, presynaptic A2A receptors localized in striatal glutamatergic terminals
could be responsible for the counteracting effects of the A2A receptor antagonist on the
reinforcing effects of cannabinoids. In that case, A2A receptor antagonists should also
counteract THC-induced, but not cocaine-induced, dopamine release in the nucleus
accumbens shell. In fact, by using in vivo microdialysis in freely-moving rats, we found that
a behaviorally active dose of MSX-3 significantly counteracted THC-induced increases in
extracellular dopamine levels in the nucleus accumbens shell induced by THC. These effects
of MSX-3 on reinforcement and dopamine release were selective, occurring with
cannabinoids but not with cocaine. The lack of effect of the A2A receptor antagonist in
cocaine-induced dopamine release could not be explained by a ceiling effect of the dose of
cocaine used (3 mg/kg, i.p.), since higher cocaine doses can produce much more pronounced
effects (see e.g., Tanda et al. 2005). The finding that an A2A receptor antagonist was able to
reduce cannabinoid-induced self-administration (in monkeys) and dopamine release (in
rats), yet failed to attenuate cannabinoid-induced reinstatement is intriguing. It reinforces the
hypothesis that different mechanisms and brain circuits are involved in these phenomena;
that dopamine is involved in cannabinoid self-administration, but its involvement in the
reinstatement of cannabinoid drug-seeking may not be as pronounced (Kalivas & Volkow
2005; Koob & Volkow 2010; Robbins & Everitt 1996).
In the squirrel monkeys, a low 1 mg/kg dose of MSX-3 significantly attenuated self-
administration of training doses of THC or anandamide that maintained maximal responding
under a FR schedule but did not potentiate reinforcing effects of lower threshold doses of
both drugs. A higher dose (3 mg/kg) of MSX-3 further attenuated self-administration of
training doses of THC or anandamide under the FR schedule, but it potentiated the effect of
threshold doses of both drugs. These opposite effects obtained with the 1 and 3 mg/kg doses
of MSX-3 could be due to a preferential presynaptic effect with the lower dose of MSX-3,
with the appearance of a postsynaptic effect with higher doses. Importantly, MSX-3 (at any
dose tested) did not alter the reinforcing effects of cocaine or food pellets, and did not
reinstate extinguished drug-seeking behavior in monkeys that had previously self-
administered THC or cocaine under a FR schedule. These findings demonstrate that
adenosine A2A receptors selectively modulate the reinforcing effects of cannabinoids. The
significant and selective results obtained with the lower dose of MSX-3 suggest that
adenosine A2A antagonists acting preferentially at presynaptic A2A receptors might
selectively reduce the reinforcing effects of cannabinoids that lead to their abuse. However,
the appearance of potentiating rather than suppressing effects on cannabinoid reinforcement
at the higher dose of MSX-3 would likely preclude the use of such a compound as a
medication for cannabis abuse. Adenosine A2A receptor antagonists with more selectivity
for presynaptic receptors could have a potential as medications for treatment of cannabis
abuse.
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Effects of different doses of MSX-3 on peak self-administration responding maintained by
40 μg/kg injections of anandamide, 4 μg/kg injections of THC, 30 μg/kg injections of
cocaine or food pellets. Numbers of injections or pellets per session (upper panels) and rates
of responding (lower panels) are presented as a function of dose of MSX-3 (0.1, 0.3, 1.0,
and 3.0 mg/kg; i.m. 5 min before the session). Each point represents the mean (± S.E.M.) of
three sessions under each MSX-3 dose condition from 3 (THC and cocaine), 4 (anandamide)
or 5 (food) monkeys per each group. * P<0.05, ** P<0.01, post-hoc comparisons with the
vehicle (V) conditions (Dunnett's test).
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Effects of pretreatment with vehicle or MSX-3 (1 and 3 mg/kg; i.m. 5 min before the
session) on anandamide (left panel), THC (middle panel) or cocaine (right panel) dose-
response curves. Numbers of injections per session after i.m. pretreatment with vehicle or
MSX-3 are shown. Each point represents the mean (± S.E.M) from 3 (THC and cocaine) or
4 (anandamide) monkeys over three sessions under each condition.
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Effects of pretreatment with vehicle or MSX-3 (1 or 3 mg/kg; i.m. 5 min before the session)
on reinstatement of extinguished THC- (panels a, b, c) or cocaine-seeking (panels d, e, f)
behavior by a priming injection of vehicle or THC (10 or 40 μg/kg; i.v. immediately before
session). Each bar (number of injections per session) represents the mean ± S.E.M. from 3-4
monkeys for a single session at each condition. * P<0.05, ** P<0.01 - post-hoc pairwise
comparisons (Tukey test) with combination of i.p. MSX-3 vehicle (V) + i.v. THC vehicle
(V) combination.
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Effects of pretreatment with MSX-3 on THC- or cocaine-induced increases in the
extracellular concentrations of dopamine in the nucleus accumbens shell. An MSX-3 dose of
3 mg/kg was given i.p. 20 min before the administration of THC (3 mg/kg, i.p., upper panel)
or cocaine (3 mg/kg i.p., lower panel). Data represent means ± S.E.M. (n = 6-9 per group,
male Sprague-Dawley rats); * P<0.05, ** P<0.01, compared to the basal values (average of
the values from the -60, -40 and -20 periods) (ANOVA and Dunnett's test).
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